Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Progress: Atogepant for Prevention of Chronic Migraine (Japan, Phase 3)
jRCT2080225075Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of atogepant in chronic migraine (3 arms), sponsored by AbbVie Inc. Started Feb 2020; status: completed.
02
Drugs
atogepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on jRCT2080225075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225075.